Mortality in hereditary antithrombin-III deficiency--1830 to 1989.
To determine whether antithrombin-III (AT-III) deficiency leads to an excess mortality, we studied 171 individuals from ten families with a proven hereditary deficiency. 73 were classified as certainly deficient either by direct measurement of AT-III concentration or by mendelian inheritance patterns. 98 individuals had a high probability (0.5) of deficiency. The 64 deaths recorded did not exceed those expected for the general population adjusted for age, sex, and calendar period. We suggest that a policy of prophylactic anticoagulation for patients with AT-III deficiency cannot be recommended.
Rosendaal
F R
FR
Department of Clinical Epidemiology, University Hospital Leiden, The Netherlands.
Heijboer
H
H
Briët
E
E
Büller
H R
HR
Brandjes
D P
DP
de Bruin
K
K
Hommes
D W
DW
Vandenbroucke
J P
JP
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000941:Antigens / Q000032:analysis; D000990:Antithrombin III / Q000276:immunology; D020152:Antithrombin III Deficiency; D002648:Child; D002675:Child, Preschool; D004198:Disease Susceptibility; D005069:Evaluation Studies as Topic; D005260:Female; D005500:Follow-Up Studies; D030342:Genetic Diseases, Inborn / Q000453:epidemiology / Q000401:mortality*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008875:Middle Aged; D009426:Netherlands / Q000453:epidemiology; D013924:Thrombophlebitis / Q000209:etiology; D013997:Time Factors
D000941:Antigens; D000990:Antithrombin III